The Canadian Cardiovascular Society / Canadian Heart Failure Society (CCS/CHFS) Heart Failure Guidelines recommend the use of an SGLT2 inhibitor in patients with HFrEF, with or without concomitant type 2 diabetes, to improve symptoms and quality of life and to reduce the risk of hospitalization due to heart failure (HF) and/or cardiovascular (CV) mortality [14]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.